6-APB: Difference between revisions

Line 109:

| [[File:Lolol.png|17px]]''Main articles: [[Research chemicals#Toxicity and harm potential|Research chemicals § Toxicity and harm potential]]'' ''&'' ''[[Responsible use #Hallucinogens|Responsible use § Hallucinogens]]''

|}

Due to only having a short history of human use, the toxicity and harm potential is not exactly known. ~~Scientific study has come~~ to ~~the general consensus~~ that the administration of repeated or high dosages of 6-APB ~~is most certainly~~ neurotoxic and cardiotoxic<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref> in some form, ~~often~~ manifesting as deficits in cognitive, affective and psychomotor function.

Due to only having a short history of human use, the toxicity and harm potential is not exactly known. Due to its simularity to MDMA, it is likely that the administration of repeated or high dosages of 6-APB can be neurotoxic and cardiotoxic<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref> in some form, possibly manifesting as deficits in cognitive, affective and psychomotor function.

The [[Toxicity::exact toxic dosage is unknown]].

Line 118:

===Long-term health concerns===

The neurotoxicity of 6-APB is controversial. It was specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity. ~~However, scientific study has come to the general consensus that, although~~ it is physically safe to try in a responsible context, the administration of repeated or high dosages of 6-APB ~~is most certainly~~ neurotoxic in some form, ~~often~~ manifesting as deficits in cognitive, affective and psychomotor function.

The neurotoxicity of 6-APB is controversial. It was specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity. Although it is physically safe to try in a responsible context, it is completely possible that the administration of repeated or high dosages of 6-APB could be neurotoxic in some form, possibly manifesting as deficits in cognitive, affective and psychomotor function.

As with MDMA, long-term heavy use of 6-APB is likely cardiotoxic and thought to lead to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref>

@@ Line 109: / Line 109: @@
 | [[File:Lolol.png|17px]]''Main articles: [[Research chemicals#Toxicity and harm potential|Research chemicals § Toxicity and harm potential]]'' ''&'' ''[[Responsible use #Hallucinogens|Responsible use § Hallucinogens]]''
 |}
-Due to only having a short history of human use, the toxicity and harm potential is not exactly known. Scientific study has come to the general consensus that the administration of repeated or high dosages of 6-APB is most certainly neurotoxic and cardiotoxic<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref> in some form, often manifesting as deficits in cognitive, affective and psychomotor function.
+Due to only having a short history of human use, the toxicity and harm potential is not exactly known. Due to its simularity to MDMA, it is likely that the administration of repeated or high dosages of 6-APB can be neurotoxic and cardiotoxic<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref> in some form, possibly manifesting as deficits in cognitive, affective and psychomotor function.
 The [[Toxicity::exact toxic dosage is unknown]].
@@ Line 118: / Line 118: @@
 ===Long-term health concerns===
-The neurotoxicity of 6-APB is controversial. It was specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity. However, scientific study has come to the general consensus that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of 6-APB is most certainly neurotoxic in some form, often manifesting as deficits in cognitive, affective and psychomotor function.
+The neurotoxicity of 6-APB is controversial. It was specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity. Although it is physically safe to try in a responsible context, it is completely possible that the administration of repeated or high dosages of 6-APB could be neurotoxic in some form, possibly manifesting as deficits in cognitive, affective and psychomotor function.
 As with MDMA, long-term heavy use of 6-APB is likely cardiotoxic and thought to lead to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref>